- Home
- MIRA vs BGLC Comparison
MIRA vs BGLC Comparison
Compare MIRA & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- BGLC
- Stock Information
- Founded
- MIRA 2020
- BGLC 2017
- Country
- MIRA United States
- BGLC Malaysia
- Employees
- MIRA N/A
- BGLC N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- BGLC Medical Specialities
- Sector
- MIRA Health Care
- BGLC Health Care
- Exchange
- MIRA Nasdaq
- BGLC Nasdaq
- Market Cap
- MIRA 17.1M
- BGLC 7.6M
- IPO Year
- MIRA 2023
- BGLC N/A
- Fundamental
- Price
- MIRA $1.05
- BGLC $0.38
- Analyst Decision
- MIRA Strong Buy
- BGLC
- Analyst Count
- MIRA 2
- BGLC 0
- Target Price
- MIRA $14.00
- BGLC N/A
- AVG Volume (30 Days)
- MIRA 552.1K
- BGLC 116.1K
- Earning Date
- MIRA 11-11-2024
- BGLC 11-20-2024
- Dividend Yield
- MIRA N/A
- BGLC N/A
- EPS Growth
- MIRA N/A
- BGLC N/A
- EPS
- MIRA N/A
- BGLC N/A
- Revenue
- MIRA N/A
- BGLC $9,183,168.00
- Revenue This Year
- MIRA N/A
- BGLC N/A
- Revenue Next Year
- MIRA N/A
- BGLC N/A
- P/E Ratio
- MIRA N/A
- BGLC N/A
- Revenue Growth
- MIRA N/A
- BGLC N/A
- 52 Week Low
- MIRA $0.51
- BGLC $0.31
- 52 Week High
- MIRA $6.40
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- MIRA 38.97
- BGLC 41.00
- Support Level
- MIRA $1.04
- BGLC $0.38
- Resistance Level
- MIRA $1.20
- BGLC $0.49
- Average True Range (ATR)
- MIRA 0.07
- BGLC 0.02
- MACD
- MIRA 0.02
- BGLC -0.00
- Stochastic Oscillator
- MIRA 19.44
- BGLC 32.66
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.